The aim of this study was to compare the efficacy of lamivudine vs entecavir in the prevention of hepatitis B virus (HBV) reactivation in HBV surface Ag (HBsAg)-positive patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 216 consecutive patients were enrolled and retrospectively reviewed. Of these patients, 119 received lamivudine and 97 received entecavir. The median treatment duration to complete virological response in patients with baseline HBV-DNA levels 410 5 copies/mL was 2.0 months in the entecavir group, significantly shorter than that of the lamivudine group. After a median follow-up of 24 months post transplantation, the cumulative incidence rates of HBV reactivation at 6, 12 and 24 months following transplantation were 3.0%, 7.0% and 24.0% in the lamivudine group, and 0%, 0% and 2.0% in the entecavir group, respectively. In addition, entecavir treatment was associated with lower cumulative incidence rates of severe hepatitis caused by HBV reactivation. Mutations leading to drug resistance were detected in 25 patients in the lamivudine group and in only one patient in the entecavir group. Our data indicate that compared with lamivudine, entecavir has more potent antiviral efficacy and may be a better choice for prophylaxis of HBV reactivation in HBsAg-positive allo-HSCT recipients.
INTRODUCTION
Hepatitis B virus (HBV) infection is currently a major health problem worldwide. It can lead to acute and chronic hepatitis, hepatic cirrhosis and hepatocellular carcinoma. China is an endemic area for HBV infection; ∼ 10% of the normal population is HBV surface Ag (HBsAg) positive.
1,2 Because of repeated blood transfusions and immunocompromised states, patients with hematological diseases are more prone to HBV infection, with an HBsAg-positive rate of 20-24%. [3] [4] [5] With advances in transplantation technology, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been applied extensively to treat benign and malignant hematological diseases. During allo-HSCT, HBsAg-positive patients are at high risk of developing HBV reactivation in the absence of antiviral prophylaxis. In such cases, they suffer from varying degrees of liver function damage and even life-threatening fulminant hepatitis. Therefore, HBV infection severely affects the efficacy of transplantation and patient survival.
It is recommended that HBV carriers undergoing allo-HSCT be treated with anti-HBV nucleoside drugs. [6] [7] [8] Lamivudine and entecavir are the two drugs most extensively used to treat HBV carriers. Some retrospective and prospective studies have indicated that lamivudine and entecavir are both effective for controlling HBV reactivation in allo-HSCT recipients. 9, 10 However, comparative studies on the efficacy and safety of these two drugs are rarely reported. In addition, the sample sizes are small and follow-up times are short in these studies, thus introducing the potential for skewed results. Here, 216 HBsAg-positive patients who underwent allo-HSCT were retrospectively investigated as a means to compare the efficacy and safety of lamivudine vs entecavir for prophylaxis of HBV reactivation and hepatitis after allo-HSCT.
PATIENTS AND METHODS

Patients and eligibility criteria
A total of 259 consecutive patients who underwent allo-HSCT at the authors' institution between March 2008 and March 2014 were screened for this retrospective study. The inclusion criteria were: (1) deemed HBsAgpositive via detection of serum HBV immunity markers before transplantation; (2) received lamivudine or entecavir for HBV prophylaxis during transplantation; and (3) achieved complete virological response (defined as undetectable HBV-DNA levels) within 1 month after transplantation. The exclusion criteria were: (1) received grafts from HBsAg-positive donors; (2) with hepatitis A or C infection; (3) received other antiviral drugs, such as adefovir dipivoxil, interferon-α or HBV immunoglobulin as first-line treatment; and (4) received anti-HBV vaccination. The transplant database and electronic medical records were reviewed for demographic characteristics, including age, sex, donor type, HLA typing, stem cell source, number of CD34 + cells per graft, conditioning regimen and GvHD prophylaxis, as well as outcomes of interest. The study was performed in accordance with the modified Helsinki declaration, and the protocol was approved by the ethical review board of the authors' institute before initiation.
Transplantation
Four myeloablative conditioning regimens were used for our patients, including TBI+cyclophosphamide (CY), busulfan (BU)+CY, BU+fludarabine (FLU) and an intensified myeloablative conditioning regimen consisting of FLU, cytarabine (Ara-C), TBI and CY. Generally, the conditioning regimen was selected based on the patient's diagnosis and disease status at the time of transplantation. Those with acute myeloid leukemia in CR received BU+CY or BU+FLU. Those with ALL in CR received TBI+CY. Patients with acute biphenotypic leukemia and those not in remission received the intensified conditioning regimen. Cyclosporine A (CsA)+methotrexate (MTX) (on days +1 and +3) was administered to patients not in remission undergoing matched sibling donor transplants, whereas CsA+MTX (on days +1, +3 and +6) was administered to patients in CR undergoing matched sibling donor transplants for GvHD prophylaxis. CsA+MTX+anti-thymocyte globulin (ATG; Thymoglobulin, Genzyme, Cambridge, MA, USA) (total ATG doses of 7.5 mg/kg, on days − 3 to − 1) were used in patients undergoing matched unrelated donor transplants. CsA+MTX+ATG (total ATG doses of 7.5 to 10 mg/kg, on days − 3 to 0)+mycophenolate were used in patients undergoing haploidentical related donor transplants for GvHD prophylaxis.
11
Nucleoside drug therapy Generally, the choice of antiviral drugs was determined by the responsible physician according to the standards of clinical practice at the authors' institute and local prescribing guidelines. On a daily basis, 100 mg lamivudine was administered orally, and 0.5 mg entecavir was administered orally each day. Treatment was started at least 1 month before transplantation. Withdrawal of antiviral drugs was considered when immunosuppressant treatments had been discontinued for 6 months, provided that HBV-DNA testing continued to be negative and normal liver function was achieved during this time. Patients initially receiving lamivudine treatment who developed HBV reactivation were switched to 1 mg/day entecavir.
HBV and biochemical liver tests
All patients received routine examinations to determine baseline HBV serum markers as well as complete biochemical liver testing before anti-HBV therapy. The HBV serum markers included HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc (determined using an AxSYM chemiluminescence analyzer (Abbott Laboratories, Abbott Park, IL, USA); the lowest detection limit was 12 IU/mL) and HBV-DNA (determined using the LightCycler fluorescent quantitative PCR system (Roche, Basel, Switzerland); the lowest detection limit was 10 3 copies/mL). Routine examinations of the abovementioned HBV serum markers were also performed on all donors at the time of registration as an allo-HSCT donor. The liver function biochemical indicators included alanine aminotransferase, aspartate aminotransferase, total bilirubin and indirect bilirubin. The above indicators were measured weekly from 1 month before transplantation to 3 months after transplantation, or monthly from 3 months after transplantation to the end of follow-up (24 months after transplantation). Patients who were found to 
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have abnormal parameters in liver function tests during the follow-up period were also examined for serum levels of anti-hepatitis A virus IgM antibodies, anti-hepatitis E virus IgM antibodies, hepatitis C virus RNA, EBV DNA and CMV DNA. Liver imaging and related examinations were conducted based on patients' clinical conditions. For patients with confirmed HBV reactivation, direct sequencing of PCR products was performed using a Qiagen MinElute Gel Extraction Kit (Qiagen, Venlo, The Netherlands) to detect HBV drug-resistance mutations in serum samples collected from these patients. Meanwhile, the same sequencing procedure was carried out for cryopreserved serum samples (stored at − 80°C) collected from these patients before anti-HBV therapy.
Evaluation points and definitions
The primary focus of this study was HBV reactivation and hepatitis infection following transplantation. HBV reactivation was defined as either an increase in serum HBV-DNA levels of more than 10 times the preexacerbation baseline in patients who remained HBV-DNA positive, or as a change in serum HBV-DNA from negative to positive detected in two consecutive tests performed 5 days apart. 12 Hepatitis associated with HBV reactivation was characterized by a threefold or greater increase in serum alanine aminotransferase levels that exceeded the upper limit of normal (ULN) or by an absolute increase in alanine aminotransferase of more than 100 U/L combined with hepatitis infection following HBV reactivation with the absence of clinical features suggestive of veno-occlusive disease, GvHD, drug-induced hepatitis or super infection with CMV or HSV. 13 The severity of hepatitis was defined as mild, moderate and severe based on alanine aminotransferase levels of ⩽ 2 × ULN, 2-5 × ULN and 45 × ULN, respectively. 14 
Statistical analysis
All statistical analyses were performed using SPSS 16.0 software (SPSS, Chicago, IL, USA). For categorical variables, data are expressed as counts and percentages. For numerical variables, normality was tested using the D'Agostino-Pearson omnibus normality test. Data with normal distribution are presented as mean ± s.d. Either Fisher's exact test for categorical variables or Student's t-test at equal variance for numerical variables was used to compare differences between the lamivudine and entecavir groups. Cumulative incidence curves were used to calculate the incidence of HBV reactivation and HBV reactivation-related hepatitis for both groups. Differences between cumulative incidence curves were tested using the log rank test. Univariate and multivariate Cox regression analyses were used to identify risk factors that predispose patients to HBV reactivation and related hepatitis infection. Variables for the multivariate model were selected using backward stepwise elimination using significance of 40.05 as the criterion for removal from the model. A two-tailed value of P o0.05 was considered statistically significant.
RESULTS
Baseline characteristics of patients A total of 216 HBsAg-positive patients who met the inclusion criteria were enrolled for this retrospective study. Of these patients, 119 received lamivudine and 97 received entecavir before allo-HSCT. Baseline characteristics such as age, gender, treatment duration before allo-HSCT, donor type, HLA typing, stem cell source, conditioning and GVHD prophylaxis were comparable in both groups (Table 1) . Before antiviral therapy, 48 patients (40.3%) in the lamivudine group and 41 (42.3%) in the entecavir group had a HBV-DNA level of ⩾ 10 5 copies/mL, whereas 88 (73.9%) in the lamivudine group and 75 (77.4%) in the entecavir group had detectable HBV-DNA levels. For patients with ⩾ 10 HBV reactivation and drug-resistance mutations After a median follow-up time of 24 months post transplantation (range: 3.7-24 months), 28 patients (23.5%) in the lamivudine group and 2 patients (2.1%) in the entecavir group experienced HBV reactivation (P o 0.001). Of these patients, 22 had baseline HBV-DNA levels of ⩾ 10 5 copies/mL (20 in the lamivudine group and 2 in the entecavir group), whereas 8 had baseline HBV-DNA levels of 10 3 -10 5 copies/mL (all in the lamivudine group). The median times to HBV reactivation for the two groups were 17.7 months (range: 3.7-23.7 months) and 19.8 months (range: 18.0-21.5 months), respectively. The cumulative incidence rates of HBV reactivation at months 6, 12 and 24 following transplantation were 3.0, 7.0 and 24.0% in the lamivudine group, and 0, 0 and 2.0% in the entecavir group (P o 0.001; Figure 1 ). Figure 1 . Cumulative incidence curves of HBV reactivation in the lamivudine and entecavir groups after allo-HSCT. Differences between cumulative incidence curves were tested by the log rank test. A full color version of this figure is available at the Bone Marrow Transplantation journal online.
All patients with HBV reactivation underwent testing for drug-resistance mutations, and the results are summarized in Table 2 . The incidence rates of drug-resistance mutations were 21.0% (25 of 119 patients) in the lamivudine group and 1.0% (1 of 97 patients) in the entecavir group (P o 0.001). The median times to onset of drug-resistance mutations for the two groups were 18.0 months (range: 3.7-23.7 months) and 18.0 months post transplantation, respectively. Furthermore, primary drugresistance mutations were determined using the cryopreserved serum samples collected before anti-HBV therapy. The results showed that the incidence rates of primary drug-resistance mutations were 4.2% (5 of 119 patients) in the lamivudine group and 0% (none of 97 patients) in the entecavir group.
Occurrence of hepatitis from HBV reactivation In the lamivudine group, 18 of 28 patients with HBV reactivation (64.3%) developed varying degrees of hepatitis, including 13 cases of mild/moderate hepatitis and 5 cases of severe hepatitis. The median times to onset of mild/moderate and severe hepatitis were 19.4 (range: 6.5-23.7 months) and 5.5 months (range: 3.7-11.8 months), respectively. In the entecavir group, however, only one patient with HBV reactivation developed a case of mild self-healing hepatitis that occurred at 18.0 months post transplantation.
The 2-year cumulative incidence rate of hepatitis from HBV reactivation was 15.1% and 1.0% in the lamivudine and entecavir groups, respectively. At months 6, 12 and 24 post transplantation, the cumulative incidence rates of any severity of HBV reactivationrelated hepatitis were 3.0, 7.0 and 15.0% in the lamivudine group, and 0, 0 and 1.0% in the entecavir group (P = 0.001; Figure 2a ). For severe hepatitis, cumulative incidence at the three time points mentioned were 3.0, 3.0 and 4.0% in the lamivudine group, and 0, 0 and 0% in the entecavir group (P o 0.001; Figure 2b ).
In the lamivudine group, 4 of 5 patients (80.0%) with severe hepatitis died of multiple organ failure secondary to hepatitis. Nevertheless, all 13 patients with mild/moderate hepatitis were cured after switching to 1 mg/day entecavir for anti-HBV therapy. In the entecavir group, the patient who developed hepatitis was cured after supportive treatment.
In order to identify predisposing risk factors for HBV reactivation and subsequent hepatitis infection following allo-HSCT, we performed univariate and multivariate analyses using the Cox proportional hazard model. The results are summarized in Table 3 . Univariate analysis demonstrated that drug assignment was a significant risk factor for HBV reactivation and subsequent hepatitis. Patients treated with lamivudine had a considerably higher risk of HBV reactivation and subsequent hepatitis than Adverse reactions Adverse reactions (ADRs) occurring with a frequency of 45% in both treatment groups are listed in Table 4 . There was no statistical difference in the proportion of patients experiencing these ADRs between the two groups. Most ADRs were mild in severity and did not require medical intervention or discontinuation of the treatment. No grade 3-4 drug-related hematological or renal toxicities or abnormal laboratory findings occurred during treatment.
DISCUSSION
Lamivudine and entecavir are the most extensively used first-line nucleoside drugs. Currently, however, comparative studies on the efficacy and safety of these two drugs in controlling HBV reactivation in allo-HSCT recipients are rarely reported. 10, 15, 16 To our knowledge, this is the first comparison study with a large sample size and long-term follow-up involving allo-HSCT Cumulative incidence curves of any severity of HBV reactivation-related hepatitis (a) and severe hepatitis (b) in the lamivudine and entecavir groups following HSCT. Differences between cumulative incidence curves were tested using the log rank test. A full color version of this figure is available at the Bone Marrow Transplantation journal online.
recipients being treated for prophylaxis of HBV reactivation. The results showed that, as compared with lamivudine, entecavir may significantly reduce the incidence of HBV reactivation and associated hepatitis, as well as exhibit lower drug resistance and stronger antiviral activity in HBsAg-positive allo-HSCT recipients.
These results imply that entecavir may be a better choice than lamivudine for prophylaxis of HBV reactivation in allo-HSCT patients. Drug-resistance mutations are generally considered to be a major factor behind HBV reactivation and can be divided into primary and secondary mutations. Several studies have revealed that the 2-year incidence rate of drug-resistance mutations for lamivudine is significantly higher than that of entecavir (18% vs 1%) in immunocompetent patients with chronic HBV infection. 16, 17 Our study showed that the 2-year incidences of drug-resistance mutations were 21.0% for lamivudine and 1.0% for entecavir in allo-HSCT recipients, and this is consistent with outcomes seen in immunocompetent patients. These findings imply that the incidence of drug-resistance mutations might not be associated with impaired immune function in allo-HSCT patients. Our study also showed that the incidence of drugresistance mutations increased with prolonged lamivudine treatment, and that the median time to onset of drug-resistance mutations was 18 months post transplantation. Our results suggest that entecavir may be a better choice for patients who require long-term prophylaxis against HBV reactivation, such as those undergoing allo-HSCT. Moreover, in our study, primary drugresistance mutations were found in 4.2% of patients receiving prophylactic lamivudine, but in none of the patients receiving prophylactic entecavir. Therefore, routine screening for primary drug-resistant strains should be considered when lamivudine is used as prophylaxis and treatment for HBV. Several studies have proved that entecavir has greater anti-HBV efficacy than lamivudine in patients with chronic HBV infection. 18, 19 In this study, faster reduction of HBV viral loads to undetectable levels in the entecavir group also suggests that entecavir possesses better antiviral activity than lamivudine, and this may be another reason for the lower incidence of HBV reactivation seen in the entecavir group vs the lamivudine group. [20] [21] [22] In this study, in patients receiving transplants from donors with a natural immunity to HBV (HBsAb and HBcAb positive), both entecavir and lamivudine produced higher rates of HBsAg seroclearance and shorter times to HBsAg seroclearance than those reported in chronic HBV-infected patients. 23 These results were similar to findings of several previous studies that reported a HBsAg seroclearance rate of ∼ 70% and a median onset time of ∼ 2.4 months (range: 1.5-3.5 months) in allo-HSCT recipients. 24, 25 Collectively, these findings indicate that the adoptive transfer of HBV immunity from donors with natural immunity to HBV might be a major factor affecting allo-HSCT recipients. However, in our study, along with the continued use of nucleoside drugs (lamivudine or entecavir), all recipients with HBsAg seroclearance achieved sustained virological response (HBsAg negative and HBV-DNA undetectable); none of them developed HBV Prophylaxis of HBV reactivation in allo-HSCT recipients J Shang et al reactivation by the end of follow-up. Our results were consistent with a study by Hui et al., 24 suggesting that nucleoside antiviral drugs and adoptive transfer of HBV immunity have a synergistic effect on sustained HBV clearance in allo-HSCT recipients.
Patients undergoing allo-HSCT with HBV reactivation were at high risk of developing HBV-related hepatitis. 26 Our results showed that the incidence of HBV-related hepatitis was significantly higher in the lamivudine group than in the entecavir group because of the high incidence rate of HBV reactivation associated with lamivudine. More importantly, use of lamivudine was also associated with a considerably increased incidence rate of severe hepatitis. In our study, however, patients who developed resistance to lamivudine remained sensitive to entecavir treatment, suggesting that entecavir may be a potential candidate for salvage therapy after the development of lamivudine resistance. In addition, we found that the median time to onset of severe hepatitis was 5.5 months post transplantation in the lamivudine group, similar to the period of immunosuppression withdrawal and immune reconstruction. A reasonable interpretation of this finding is that HBV hepatitis is associated with immune-mediated liver cell injury. 27 Meanwhile, this result indicates that in order to reduce the incidence of severe HBV-related hepatitis, it should be required that the HBV viral load is closely monitored during the period of immune reconstruction.
Patients undergoing allo-HSCT usually experience a decline in the function of important organs such as the heart, lung and kidneys. Therefore, ADRs associated with long-term use of nucleoside drugs are worthy of investigation. The ADR data of this study revealed that long-term treatment with either lamivudine or entecavir only resulted in a low incidence of mild ADRs, suggesting that both drugs have favorable safety profiles.
Several limitations of this study should be addressed here. The major limitation is its retrospective and nonrandomized nature that may have introduced inherent selection biases that may weaken the conclusions. Another limitation is that all patients were from a single institution, and this might reduce the generalizability of the conclusions.
In conclusion, the current study indicates that entecavir can significantly reduce the incidence rate of HBV reactivation and associated hepatitis as compared with lamivudine. Thus, it is particularly suitable for patients who have high baseline HBV viral loads and require prolonged antiviral treatment for the prevention of HBV reactivation. Our findings offer rational therapeutic strategies for the prophylaxis of HBV reactivation in allo-HSCT patients.
